1 / 13

Antiplatelet Drugs and Their Role in Preventing Thrombosis

Learn about the principles of antiplatelet drugs, including mechanisms of action, inhibitors, and therapeutic efficacy in preventing arterial thrombosis. Discover how drugs like aspirin, clopidogrel, and ticlopidine target platelet function to reduce clot formation.

kmorgan
Download Presentation

Antiplatelet Drugs and Their Role in Preventing Thrombosis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Antiplatelet Drugs - Principles Benedict R. Lucchesi, M.D., Ph.D. Department of Pharmacology University of Michigan Medical School

  2. Plateletactivation Plateletaggregation Thrombin ADP Collagen TXA2 Fibrinogen Fibrin Prothrombin THROMBUS PlasmaClottingcascade TissueFactor • Thrombin is a critical mediator in coagulation • Elicits multiple responses in platelets

  3. Platelet Activation - Arterial Thrombus Formation Fibrinogen Platelet GPIIb/IIIa (Fibrinogen) Receptor Release Platelet 1 2 3 1=adhesion 2=activation & release 3=aggregation Endothelial Cell - Injury

  4. Inhibitors of the Arachidonic Acid Pathway • Cyclooxygenase Inhibitors • Aspirin • Ibuprofen • Indomethacin • Sulfinpyrazone • Aspirin does impair the aggregation response to epinephrine, ADP or thrombin and does not affect subendothelial platelet adhesion.

  5. Modifiers of Platelet Cyclic AMP • Agents that increase cyclic AMP will inhibit platelet aggregation. Increases in cyclic AMP are achieved in two ways: • stimulation of adenylate cyclase • inhibition of phosphodiesterase • Prostacyclin and Derivatives -Increases cAMP • Therapeutic use limited by side effects • Dipyridamole - PDE inhibitor • Therapeutic efficacy is questionable

  6. Nitrates • Nitrates (nitroglycerin, isosorbide dinitrate, etc.) undergo conversion in the platelet to yield nitric oxide (NO). • NO activated platelet guanylate cyclase (cGMP) resulting in an inhibition of platelet aggregation • Nitrates may also increase synthesis of prostacyclin by the endothelial cells • The full potential of nitrates as antiplatelet drugs is relatively unexplored.

  7. Ticlopidine (Ticlid™) • Clopidogrel (Plavix™) • Prolongs bleeding time • Inhibits platelet aggregation in response to ADP, but not to epinephrine, arachidonic acid, 5-HT, thrombin, etc. • Antiplatelet effects develop slowly - 24 to 48 hours from initial dosing. • Onset of action may be increased with large oral dose.

  8. Antiplatelet Therapy in Patients with Ischemic Heart Disease • Acetylsalicylic Acid (Aspirin) • Ticlopidine (Ticlid™) • Clopidogrel (Plavix™) • Dipyridamole (Persantin™) • Aspirin+ Dipyridamole(Aggrenox™) • Abciximab (7E3 Antibody; ReoPro™) • Eptifibatide (Integrilin™) • Tirofiban (Aggrestat™)

  9. Ischemic Heart Disease and Platelet Function • Patients with ischemic heart disease and abnormal coronary artery anatomy are at an increased risk for: • activation of circulating blood platelets • platelet vessel wall interactions • platelet adhesion and intravascular aggregation • episodic, transient interruptions in coronary artery blood flow - transient ischemic events • occlusive thrombus formation - prolonged regional myocardial ischemia - infarction.

  10. Altered Platelet Function Mechanisms associated in arterial thrombus formation 1. exposure of the circulating blood to a thrombo-genic surface • injured endothelial surface and exposure of subendothelial structures - collagen • atheromatous lesions on vessel wall - leading to turbulent flow • rupture of the fibrous cap of the atheromatous lesion and exposure of lipids, collagen, thrombogenic contents.

  11. Altered Platelet Function Mechanisms associated in arterial thrombus formation (continued) 2. A sequence of platelet related events, involving, • platelet adhesion • platelet aggregation • release of platelet components that promote • further aggregation • vasoconstriction • activation of the coagulation cascade

  12. Altered Platelet Function Mechanisms associated in arterial thrombus formation (continued) 3. Activation of the clotting mechanism with an important role for thrombin.... • formation of fibrin • stabilization of platelet aggregate/thrombus • activation of the platelet to enhance aggregation • activation of thrombomodulin/ProteinC/ inhibi-tion of fVIIIa and fVa

More Related